El interés en corto de Twist Bioscience da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Twist Bioscience. Los datos de interés en corto se actualizan cada dos semanas.

Twist Bioscience (NASDAQ:TWST) Bolsa, Informe de interés en corto

Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Equities

News

Markets

ETFs

ILMN

PATH

PLTR

ROKU

TWST

Ark Invest vendió más de 135.000 acciones de Palantir Technologies Inc. tras su récord en bolsa. ¿Estrategia o señal de alerta?

Cathie Wood reduce posición en Palantir (PLTR) tras resultados récord: ¿Oportunidad o advertencia?

Twist Bioscience Corporation - Common Stock

Twist Bioscience Corp

Trading Ideas

SKYE

Skye Bioscience Shares Halted On Circuit Breaker To The Upside, Stock Now Up 52.7%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham analyst Chris Pierce initiated coverage on Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) with a Buy rating and announced a price target of $10. Aurora Innovation shares closed at $6.03 on Monday. <a href="https://www.benzinga.com/quote/AUR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Andrew Andersen initiated coverage on SiriusPoint Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) with a Hold rating and announced a price target of $17. SiriusPoint shares closed at $16.43 on Monday. <a href="https://www.benzinga.com/quote/SPNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Adam Maeder initiated coverage on RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) with a Neutral rating and announced a price target of $18. RxSight shares closed at $14.42 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AUR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="580" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114-1024x580.png" alt="" class="wp-image-872123" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114-1024x580.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44806916/citigroup-bank-of-america-and-3-stocks-to-watch-heading-into-tuesday">Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Analyst Ratings

HUBS

RXST

SPNT

This Aurora Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

Citigroup analyst Thomas Palmer maintains Archer-Daniels-Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) with a Neutral and lowers the price target from $51 to $49.

Price Target

Citigroup Maintains Neutral on Archer-Daniels-Midland, Lowers Price Target to $49

The statistically significant responder analysis results for Mytesi&#xAE; (crofelemer) in the Phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the <a href="https://sabcs.org/Symposium-Overview-2024">San Antonio Breast Cancer Symposium</a>
Late-breaker abstract accepted by <a href="https://mascc.org/annualmeeting2025/">MASCC</a> shows additional significant results for breast cancer subgroup
Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer
A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 15, 2025 / <a href="https://pr.report/9ein">Jaguar Health, Inc.</a> <a href="https://pr.report/9eio">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or the "Company") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for presentation as an oral rapid e-poster at MASCC's June 26-28, <a href="https://pr.report/9eip">2025 Annual Meeting</a> in Seattle, Washington. The authors include Pravin Chaturvedi, PhD, who is Jaguar's Chief Scientific Officer and Chair of Napo's Scientific Advisory Board, as well as leading oncologists and cancer patient advocates.
The abstract is titled OnTarget: Crofelemer or Placebo for the Prophylaxis of Diarrhea in Adults with Solid Tumors Initiating Targeted Therapy ± Chemotherapy (Tt/C)
"We're very pleased about the acceptance by MASCC of this new abstract, which describes the proportion of breast cancer patients who were continuous responders for the entire 3-month period of the OnTarget trial compared to breast cancer patients in the placebo arm of the study," said Lisa Conte, Jaguar's president and CEO.
"As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe the published results of crofelemer for the prophylaxis of cancer therapy-related are very exciting and compelling," said Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who serves on Napo's Scientific Advisory Board (SAB).
As announced, the U.S. Food and Drug Administration (FDA) has granted Napo a Type C Meeting in the second quarter of 2025 to discuss the responder analysis in the prespecified subgroup of patients with breast cancer for crofelemer in Napo's Phase 3 OnTarget trial. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy. The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025,1 and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022.2
"Diarrhea is a common side effect of targeted cancer therapies and can lead to dose changes, treatment delays, or cessation of treatment altogether, all of which can impact patient outcomes. We are very happy to have been granted a meeting with the FDA to review the positive OnTarget results in breast cancer patients and our goal is to discuss the most efficient pathways to make crofelemer - our novel, oral plant-based prescription medicine - available to this patient population for cancer therapy-related diarrhea (CTD)," said Conte.
Members of Napo's SAB are expected to join Jaguar representatives at the FDA meeting in the second quarter of 2025.
As previously announced, the initial top line results from the OnTarget study showed that the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types. The subgroup analysis in adult breast cancer patients indicates that crofelemer achieved significant results in this subgroup.
Napo today also announced that a second late-breaker abstract, related to the results of a recent Napo-sponsored screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting. The abstract is titled Beyond the Pain: Patient Insights on Oral Mucositis in Cancer Treatment.
"Oral mucositis is a common, painful, and life-altering side effect of cancer treatment, frequently disrupting eating, speaking, sleeping, and social interactions. Capturing real-world patient experiences and insights can help to identify patient priorities and co-create solutions to support prevention and management of oral mucositis and enhance quality of life," said Stacey Tinianov, 11-year cancer survivor and founder of <a href="https://pr.report/9eiq">Advocates for Collaborative Education</a> who serves on Napo's SAB. "I am delighted and honored that the results of the screening survey and focus group will be presented at MASCC's Annual Meeting this June."
Ms. Tinianov coordinated the screening survey and focus group in conjunction with cancer patients who serve as Ambassadors for Napo's ongoing <a href="https://pr.report/9eir">Make Cancer Less Shitty</a> (MCLS) patient advocacy program. The goal of the MCLS program is to drive awareness of cancer supportive care gaps and needs, bring together patients, advocates, researchers, and clinicians, and, most importantly, to amplify the voice of patients about the importance of supportive care.
"Oral mucositis has impacted my daily life constantly since 2016. Without proper supportive care, I have raw mouth sores and ulcerations from my gums and lips all the way down my throat. When severe, it impacts what I am able to eat, how I'm able to eat, and sometimes my ability to talk. The pain and irritation from oral mucositis affects my sleep and my self-confidence," said JJ Singleton, a metastatic colon cancer survivor and an Ambassador for Napo's MCLS patient advocacy program.
<a href="https://pr.report/9eis">MASCC</a> is an international, interdisciplinary organization dedicated to the practice, education and research of supportive care in cancer. The organization's mission is to continually improve the supportive care of people with cancer - from diagnosis through to survival or end-of-life care.

JAGX

Jaguar Health Says Late-Breaker Abstract On Addl Results In Adult Breast Cancer Patients From OnTarget Study Accepted For Presentation As Oral Rapid E-poster At MASCC Annual Meeting

Keybanc analyst Eric Gonzalez maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Overweight and lowers the price target from $64 to $60.

Keybanc Maintains Overweight on Chipotle Mexican Grill, Lowers Price Target to $60

Citigroup analyst Patrick Cunningham maintains Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) with a Neutral and lowers the price target from $85 to $64.

Citigroup Maintains Neutral on Albemarle, Lowers Price Target to $64

TMO closes near the high of the day
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/14212258/Screenshot-2025-04-14-at-5.14.58%E2%80%AFPM-1024x808.png" alt="" class="wp-image-10614" /></figure>
Thermo Fisher Scientific Inc. (TMO) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:01 AM on April 14th, a significant trading signal occurred for Thermo Fisher Scientific, Inc. (TMO) as it demonstrated a Power Inflow at a price of $444.92. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in TMO&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in TMO&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TMO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:The price at the time of the Power Inflow was $444.92. The returns on the High price ($450.84) and Close price ($449.33) after the Power Inflow are respectively 1.3% and 1.0%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Results Not indicative of Future Results

WIIM

Technicals

Opinion

Signals

Thermo Fisher Scientific Stock Up 1.3% After Key Signal

Keybanc analyst Justin Patterson maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Overweight and lowers the price target from $240 to $230.

DASH

Keybanc Maintains Overweight on DoorDash, Lowers Price Target to $230

Barclays analyst Ramsey El-Assal maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Overweight and lowers the price target from $110 to $80.

PYPL

Barclays Maintains Overweight on PayPal Holdings, Lowers Price Target to $80

<a href="https://www.canada.ca/en/department-finance/news/2025/04/canada-announces-new-support-for-canadian-businesses-affected-by-us-tariffs.html" title="https://www.canada.ca/en/department-finance/news/2025/04/canada-announces-new-support-for-canadian-businesses-affected-by-us-tariffs.html">https://www.canada.ca/en/department-finance/news/2025/04/canada-announces-new-support-for-canadian-businesses-affected-by-us-tariffs.html</a>

Macro Economic Events

Global

Economics

Canada Announces New Support For Canadian Businesses Affected By Us Tariffs; Government Intends To Provide Temporary 6-Month Relief For Goods Imported From The US That Are Used In Canadian Manufacturing, Processing And Food And Beverage Packaging, And For Those Used To Support Public Health, Health Care, Public Safety And National Security Objectives

Keybanc analyst Jason Celino maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Overweight and lowers the price target from $690 to $555.

SNPS

Keybanc Maintains Overweight on Synopsys, Lowers Price Target to $555

Keybanc analyst Justin Patterson maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and lowers the price target from $85 to $80.

UBER

Keybanc Maintains Overweight on Uber Technologies, Lowers Price Target to $80

A forthcoming U.S. regulatory framework is expected to <a href="https://www.benzinga.com/25/04/44789350/why-stablecoins-are-the-us-dollars-overlooked-advantage">supercharge the stablecoin market</a>, pushing its total value from $230 billion today to $2 trillion by the end of 2028.
According to Geoffrey Kendrick, Head of Digital Assets Research at Standard Chartered, the growth will generate $1.6 trillion in additional demand for U.S. Treasury bills, effectively absorbing the entire new T-bill issuance planned during President Trump's second term.
In a note published Monday, Kendrick said the expected passage of the GENIUS Act, which clarifies the legal treatment of stablecoins, will unlock a massive wave of demand for tokenized dollar-based instruments. 
"That growth will require an extra $1.6 trillion of US T-bills to be held as reserves," he said, adding, "That is ALL of the planned new T-bill issuance over that period."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44811440/why-the-next-generation-of-on-chain-will-be-shaped-by-ai-according-to-walletconnects-pedro-gomes">Why &#8216;The Next Generation Of On-Chain Will Be Shaped By AI&#8217;, According To WalletConnect&#8217;s Pedro Gomes</a>
Why It Matters: The GENIUS Act, already approved by the Senate Banking Committee, is expected to be passed by Congress and signed by President Donald Trump before summer.
Once enacted, it will mandate that stablecoin reserves be held in instruments with a duration of no more than 93 days. 
Kendrick expects most issuers to follow Circle's model for USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) reserves, which holds 88% of its backing in Treasury bills with an average duration of just 12 days.
If realized, the estimated $1.6 trillion in new T-bill demand would make stablecoin issuers the second-largest holders of short-term U.S. government debt, second only to money market funds, which currently hold $2.4 trillion.
Beyond Treasury markets, the boom in stablecoins could also reinforce the U.S. dollar's global influence. 
"Rising demand for USD-denominated stablecoin reserves would create additional demand for USD," Kendrick noted, arguing that this trend will "further entrench USD dominance of stablecoins" and help offset macro headwinds such as ongoing tariff disputes.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44810015/robinhood-coinbase-could-benefit-from-new-digital-asset-regulation-says-bernstein">Robinhood, Coinbase Could Benefit From New Digital Asset Regulation, Says Bernstein</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$USDC

Stablecoins To Surge To $2 Trillion By 2028, Says Standard Chartered: Here's What It Means For The Dollar

Stephens &amp; Co. analyst Tommy Moll maintains Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) with a Equal-Weight and raises the price target from $75 to $80.

FAST

Stephens & Co. Maintains Equal-Weight on Fastenal, Raises Price Target to $80

U.S. Treasury Secretary Scott Bessent hinted at confidence in the speed of trade negotiations and the stability of U.S. financial markets despite recent volatility in bonds and the dollar. The Trump administration is racing to lock in multiple agreements within <a href="https://www.benzinga.com/topic/donald-trump">a tight 90-day window. </a>
In an interview on Monday with Bloomberg's Annmarie Hordern during his visit to Buenos Aires, Bessent outlined a fast-moving agenda aimed at reshaping global trade relationships while maintaining a harder-line stance on China. He rejected claims that steep trade tariffs are a &#8220;joke.&#8221;
<h3 class="wp-block-heading">Fast-Tracking Trade, Starting With Allies</h3>
Bessent said the White House is entering a new phase of trade talks following a "90-day pause" ordered by Trump to set the stage for wide-ranging negotiations.
"We&#8217;re setting up a process and we are going to run that process. It's going to be orderly," Bessent said, noting the administration had already met with Vietnamese and Japanese officials and will continue with South Korea and Spain this week.
The goal is to finalize "agreements in principle" with a wide number of trading partners before the 90-day window closes. Bessent suggested that early movers could gain more favorable terms.
"Usually, the first person who makes a deal gets the best deal," he said.
While much attention is focused on tariff levels, Bessent said the real challenge lies in non-tariff trade barriers such as subsidies, currency manipulation and regulations that distort market access.
"It's not just about tariffs," he said. "It's the non-tariff trade barriers that are more insidious, more difficult to spot."
<h3 class="wp-block-heading">China: Strategic Rival, Not Just A Trade Partner</h3>
Pressed on whether trade policy was also a form of China policy, Bessent agreed that Latin America's economic direction was part of a broader geopolitical contest.
"We are trying to keep from happening in Latin America what has already happened in Africa," he said, referencing China's use of debt diplomacy and resource-exchange deals. He called some of Beijing's lending practices "rapacious" and warned that generations could be left poorer.
Argentina has a currency swap line of $18 billion with China's central bank. Bessent said the Trump administration hopes that, over time, Argentina will build enough foreign exchange reserves to unwind that arrangement.
As for direct trade talks with Beijing, Bessent said discussions "will come from the top," referring to President Trump and China's President Xi Jinping.
He dismissed China's claim that the new U.S. tariffs are a "joke," adding, "These are big numbers. It's far from a joke."
<h3 class="wp-block-heading">Treasury Volatility? Just Leverage Unwinding</h3>
Financial markets have been rattled by the rapid rise in Treasury yields, with the 10-year jumping nearly 50 basis points last week and the dollar – as broadly tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – weakening by almost 3%.
Still, Bessent said there's no indication of foreign selling or a broader loss of confidence in U.S. debt.
"I don't think there's a dumping," he said. "We saw increased foreign competition" in last week's long-dated Treasury auctions, including the 10-year and 30-year bonds.
Bessent attributed the price action to leveraged funds getting caught offside during a short-term spike in volatility. "I think this is one of those occasional VAR shocks that you get in the trading community."
Despite concerns voiced by investors and analysts, Bessent maintained that the U.S. dollar remains the world's reserve currency and that the administration still supports a strong dollar policy. 
"We are still a global reserve currency," he said.
<h3 class="wp-block-heading">Fed Independence, Powell's Future And Deregulation Agenda</h3>
Asked about the future of Federal Reserve Chair Jerome Powell, whose term ends in May 2026, Bessent said discussions about potential successors would begin in the fall but stressed the Fed's independence.
"Monetary policy is a jewel box—it's got to be preserved," he said.
Bessent added that markets overly focused on tariffs may be missing the broader three-part plan the administration is rolling out: tariffs, tax cuts and deregulation.
"The tariff sequencing was always going to be first," he said, adding that tax legislation is "moving quickly" and deregulation will kick in this fall. He dismissed the idea that only a tax extension is on the table, saying the GOP is showing "remarkable unity" on broader fiscal reforms.
As for his message to markets, Bessent borrowed from President Trump: "Stay cool."
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44802211/5-small-businesses-hit-trump-with-lawsuit-over-tariffs-trade-deficits-are-not-an-emergency">5 Small Businesses Hit Trump With Lawsuit Over Tariffs: Trade Deficits &#8216;Are Not An Emergency&#8217;</a></li>
</ul>
Photo: Shutterstock

Government

Regulations

Bonds

Currency ETFs

Forex

Treasuries

Econ #s

Federal Reserve

PowerShares DB US Dollar Index Bullish Fund

Bessent Says Tariffs On China Are 'Far From A Joke,' Dismisses Treasury Dumping Fears

Piper Sandler analyst Alexander Goldfarb maintains EastGroup Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGP#NYSE">EGP</a>) with a Neutral and lowers the price target from $175 to $172.

Piper Sandler Maintains Neutral on EastGroup Properties, Lowers Price Target to $172

<ul>
<li>BA</li>
<li>NVDA</li>
<li>TSLA</li>
<li>GLD</li>
<li>AAPL</li>
<li>MAGA</li>
<li>HOOD</li>
<li>D</li>
<li>RKLB</li>
<li>JD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

HOOD

MAGA

NVDA

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of April 15, 2025 (Via Swaggy Stocks)

Stephens &amp; Co. analyst Mike Scialla maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Overweight and lowers the price target from $123 to $118.

Stephens & Co. Maintains Overweight on Expand Energy, Lowers Price Target to $118

Piper Sandler analyst Alexander Goldfarb maintains BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) with a Overweight and lowers the price target from $100 to $85.

Piper Sandler Maintains Overweight on BXP, Lowers Price Target to $85

Contracts

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Received Payment From Glo-Med Networks For Delivery Of INSPIRA ART100 Systems; Revenue In Range Of ow Hundreds Of Thousands Of Dollars Relates To Delivery Of INSPIRA ART100 Systems

Comments

Twist Bioscience

Interés en corto

Twist Bioscience (NASDAQ:TWST) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL